Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708425 | 0.87 | LRRK2 (0.34) | LRRK2 | |
| SCHEMBL17708109 | 0.86 | CNR2 (0.34) | CNR2 | |
| SCHEMBL17708111 | 0.86 | LRRK2 (0.30) | LRRK2 | |
| SCHEMBL18066922 | 0.82 | KCNN4 (0.34) | LRRK2 | |
| SCHEMBL19836199 | 0.80 | LRRK2 (0.37) | LRRK2NOTUM | |
| SCHEMBL19527772 | 0.79 | SCD (0.35) | — | |
| SCHEMBL17548786 | 0.79 | SLC16A3 (0.30) | — | |
| SCHEMBL19836352 | 0.79 | — | — | |
| SCHEMBL15337286 | 0.74 | LRRK2 (0.30) | LRRK2 | |
| SCHEMBL15337288 | 0.74 | RXRA (0.35) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | LRRK2 391/4885NOTUM 1505/4885CNR2 3941/4885 |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | LRRK2 391/4885NOTUM 1505/4885CNR2 3941/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | LRRK2 391/4885NOTUM 1505/4885CNR2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.